Posttransplant malignancy

Progress in Transplantation

Volumn 14, Issue 3, 2004, Pages 193-200

  Trofe, Jennifer ^a   Beebe, Thomas M ^a   Buell, Joseph F ^a   Hanaway, Michael J ^a   First, M Roy ^a,b   Alloway, Rita R ^a   Gross, Thomas G ^a,c   Woodle, E Steve ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

^b ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CYCLOSPORIN A; DACLIZUMAB; LYMPHOBLAST ANTIBODY; OKT 3; POLYCLONAL ANTIBODY; THYMOCYTE ANTIBODY;

AGE; ALLOGRAFT; CANCER CLASSIFICATION; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CHILD; CLINICAL FEATURE; DONOR TRANSMITTER MALIGNANCY; GRAFT SURVIVAL; HUMAN; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; LONG TERM CARE; LYMPHOPROLIFERATIVE DISEASE; MALIGNANT NEOPLASTIC DISEASE; ORGAN DONOR; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATION; POSTTRANSPLANT MALIGNANCY; QUALITY OF LIFE; REVIEW; RISK FACTOR; SURGICAL TECHNIQUE; SURVIVAL; SURVIVAL RATE;

EID: 4444359464     PISSN: 15269248     EISSN: None     Source Type: Journal    
DOI: 10.7182/prtr.14.3.t7r41052414t1u20     Document Type: Review

References (64)

1. Levine AM. Lymphoma complicating immunodeficiency disorders. Ann Oncol. 1994;5(suppl 2):29-35.
2. Levine AM, Seneviratne L, Tulpule A. Incidence and management of AIDS-related lymphoma. Oncology (Huntingt). 2001;15:629-639; discussion 639-640, 645-646.
3. Kinlen LJ. Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am J Med. January 1985;78:44-49.
4. Kyllonen L, Salmela K, Pukkala E. Cancer incidence in a kidney-transplanted population. Transpl Int. 2000;13(suppl 1): S394-398.
5. Penn I. Occurrence of cancers in immunosuppressed organ transplant recipients. Clin Transpl. 1994;8:99-109.
6. Penn I, Hammond W, Brettschneider L, Starzl TE. Malignant lymphomas in transplantation patients. Transplant Proc. March 1969;1:106-112.
7. Penn I. The effect of immunosuppression on pre-existing cancers. Transplantation. 1993;55:742-747.
8. Penn I. Evaluation of transplant candidates with pre-existing malignancies. Ann Transplant. 1997;2:14-17.
9. Kasiske BL, Cangro CB, Hariharan S, et al. The evaluation of renal transplantation candidates: clinical practice guidelines. Am J Transplant. 2001;1(suppl 2):1-95.
10. Shiel A. Cancer in dialysis and transplant patients. In: Morris PJ, ed. Kidney Transplantation Principles and Practice. 5th ed. Philadelphia, Pa: WB Saunders; 2001:558-570.
11. Penn I. Some contributions of transplantation to our knowledge of cancer. Transplant Proc. 1980;12:676-680.
12. Kauffman MH, McBride MA, Cherikh WS, Spain PC, Marks WH, Roza AM. Transplant tumor registry: donor related malignancies. Transplantation. 2002;74:358-362.
13. Birkeland SA, Storm HH. Risk for tumor and other disease transmission by transplantation: a population-based study of unrecognized malignancies and other diseases in organ donors. Transplantation. 2002;74:1409-1413.
14. Kauffman HM, McBride MA, Delmonico FL. First report of the United Network for Organ Sharing Transplant Tumor Registry: donors with a history of cancer. Transplantation. 2000;70:1747-1751.
15. Buell JF, Trofe J, Hanaway MJ, et al. Transmission of donor cancer into cardiothoracic transplant recipients. Surgery. 2001;130:660-668.
16. Feng S, Buell JF, Cherikh WS, et al. Organ donors with positive viral serology or malignancy: risk of disease transmission by transplantation. Transplantation. 2002;74:1657-1663.
17. Lefrancois N, Touraine JL, Cantarovich D, et al. Transmission of medulloblastoma from cadaver donor to three organ transplant recipients. Transplant Proc. 1987;19(1 pt3):2242.
18. Stephens JK, Everson GT, Elliott CL, et al. Fatal transfer of malignant melanoma from multiorgan donor to four allograft recipients. Transplantation. 2000;70:232-236.
19. Penn I. Donor transmitted disease: cancer. Transplant Proc. 1991;23:2629-2631.
20. Penn I. Transmission of cancer from organ donors. Ann Transplant. 1997;2:7-12.
21. Penn I. Transmission of cancer with donor organs. Transplant Proc. 1988;20:739-740.
22. Buell JF, Trofe J, Sethuraman G, et al. Donors with central nervous system malignancies: are they truly safe? Transplantation. 2003;76:340-343.
23. Conlon PJ, Smith SR. Transmission of cancer with cadaveric donor organs. J Am Soc Nephrol. July 1995;6:54-60.
24. Detry O, Honore P, Jacquet N, Meurisse M. Management of recipients of hepatic allografts harvested from donors with malignancy diagnosed shortly after transplantation. Clin Transplant. 1998;12:579-581.
25. Kauffman HM, McBride MA, Cherikh WS, Spain PC, Delmonico FL. Transplant tumor registry: donors with central nervous system tumors. Transplantation. 2002;73:579-582.
26. Chui AK, Herbertt K, Wang LS, et al. Risk of tumor transmission in transplantation from donors with primary brain tumors: an Australian and New Zealand registry report. Transplant Proc. 1999;31:1266-1267.
27. Penn I. De novo malignances in pediatric organ transplant recipients. Pediatr Transplant. February 1998;2:56-63.
28. Penn I. Neoplastic complications of organ transplantation. In: Ginns LC, Cosimi AB, Morris PJ, eds. Transplantation. Maiden, United Kingdom: Blackwell Science; 1999:770-786.
29. Penn I. Why do immunosuppressed patients develop cancer? Crit Rev Oncog. January 1989;1:27-52.
30. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med. 2003;348:1681-1691.
31. Penn I. Cancers in renal transplant recipients. Adv Ren Replace Ther. 2000;7:147-156.
32. Kasiske BL, Vazquez MA, Harmon WE, et al. Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. J Am Soc Nephrol. 2000;11(suppl 15):S1-86.
33. Penn I. Occurrence of cancers in immunosuppressed organ transplant recipients. Clin Transpl 1998;12:147-158.
34. Penn I. Post-transplant malignancy: the role of immunosuppression. Drug Saf. 2000;23:101-113.
35. Sheil AG, Disney AP, Mathew TH, Livingston BE, Keogh AM. Lymphoma incidence, cyclosporine, and the evolution and major impact of malignancy following organ transplantation. Transplant Proc. 1997;29:825-827.
36. Kiberd BA, Keough-Ryan T, Clase CM. Screening for prostate, breast and colorectal cancer in renal transplant recipients. Am J Transplant. 2003;3:619-625.
37. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.6.3. Cancer risk after renal transplantation. Solid organ cancers: prevention and treatment. Nephrol Dial Transplant. 2002;17(suppl 4):32, 34-36.
38. Green M. Management of Epstein-Barr virus-induced posttransplant lymphoproliferative disease in recipients of solid organ transplantation. Am J Transplant. 2001;1:103-108.
39. Penn I. Neoplastic complications of transplantation. Semin Respir Infect. 1993;8:233-239.
40. Paya CV, Fung JJ, Nalesnik MA, et al. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation. 1999;68:1517-1525.
41. Nalesnik MA, Jaffe R, Starzl TE, et al. The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol October 1988;133:173-192.
42. Knowles DM, Cesarman E, Chadburn A, et al. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood. 1995;85:552-565.
43. Frizzera G, Hanto DW, Gajl-Peczalska KJ, et al. Polymorphic diffuse B-cell hyperplasias and lymphomas in renal transplant recipients. Cancer Res. 1981;41(11 pt 1):4262-4279.
44. Dharnidharka VR, Tejani AH, Ho PL, Harmon WE. Posttransplant lymphoproliferative disorder in the United States: young Caucasian males are at highest risk. Am J Transplant. 2002;2:993-998.
45. Nalesnik MA. Clinicopathologic characteristics of post-transplant lymphoproliferative disorders. Recent Results Cancer Res. 2002;159:9-18.
46. Bunnapradist S, Vo A, Toyoda M, et al. Posttransplantation lymphoproliferative disorder presenting as a unilateral leg mass 10 years after kidney transplantation. Transplantation. 2002;74:1648-1651.
47. Holmes RD, Sokol RJ. Epstein-Barr virus and post-transplant lymphoproliferative disease. Pediatr Transplant. 2002;6: 456-464.
48. Dotti G, Fiocchi R, Motta T, et al. Lymphomas occurring late after solid-organ transplantation: influence of treatment on the clinical outcome. Transplantation. 2002;74:1095-1102.
49. Nalesnik MA. Clinicopathologic features of posttransplant lymphoproliferative disorders. Ann Transplant. 1997;2:33-40.
50. Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet. 1993;342: 1514-1516.
51. Penn I. Posttransplant malignancies in pediatric organ transplant recipients. Transplant Proc. 1994;26:2763-2765.
52. Pearlman LS. Posttransplant viral syndromes in pediatric patients: areview. Prog Transplant. 2002;12:116-124.
53. Shapiro R, Nalesnik M, McCauley J, et al. Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression. Transplantation. 1999;68:1851-1854.
54. Boubenider S, Hiesse C, Goupy C, Kriaa F, Marchand S, Charpentier B. Incidence and consequences of post-transplantation lymphoproliferative disorders. J Nephrol. 1997;10:136-145.
55. Ho M, Jaffe R, Miller G, et al. The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children. Transplantation. 1988;45:719-727.
56. Dharnidharka VR, Sullivan EK, Stablein DM, Tejani AH, Harmon WE. Risk factors for posttransplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Transplantation. 2001;71:1065-1068.
57. Birkeland SA, Hamilton-Dutoit S. Is posttransplant lymphoproliferative disorder (PTLD) caused by any specific immunosuppressive drug or by the transplantation per se? Transplantation. 2003;76:984-988.
58. Majewski M, Korecka M, Joergensen J, et al. Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses. Transplantation. 2003;75:1710-1717.
59. Nepomuceno RR, Balatoni CE, Natkunam Y, Snow AL, Krams SM, Martinez OM. Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas. Cancer Res. 2003;63:4472-4480.
60. Trofe J, Buell JF, First MR, Hanaway MJ, Beebe TM, Woodle ES. The role of immunosuppression in lymphoma. Recent Results Cancer Res. 2002;159:55-66.
61. Cherikh WS, Kauffman HM, McBride MA, Maghirang J, Swinnen LJ, Hanto DW. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation. 2003;76:1289-1293.
62. Preiksaitis JK, Keay S. Diagnosis and management of posttransplant lymphoproliferative disorder in solid-organ transplant recipients. Clin Infect Dis. 2001;33(suppl 1):S38-46.
63. Tsai DE, Hardy CL, Tomaszewski JE, et al. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation. 2001;71:1076-1088.
64. First MR, Peddi VR. Malignancies complicating organ transplantation. Transplant Proc. 1998;30:2768-2770.